Medical device maker MicroTransponder has completed a $ 53 million series of E-Series funding led by US Venture Partners.
The increase also included participation from GPG Ventures, Exceller Hunt Ventures, Osage University Partners, Action Potential Venture Capital and Vertical Group. The company said it would use the capital to commercialize its vagus nerve stimulation system, Vivistim, an implantable device that aims to improve hand and arm mobility in stroke patients.
“Our investors are energetic about MicroTransponder’s vision to treat millions of stroke survivors who have moderate to severe upper limb injuries. Our goal has always been to establish Vivistim Paired VNS as the gold standard for stroke rehabilitation intervention. Today is the day this therapy can help more stroke survivors return to the daily activities, hobbies and experiences they love, “CEO and CEO Richard Faust said in a statement.
Oma Fertility came out of stealth last week with $ 37.5 million, including $ 29 million in equity and another $ 8.5 million in debt financing.
The starting and Serie A rounds were led by JAZZ Venture Partners, Root Ventures, Mithril Capital, Global Asset Capital and Free Solo Ventures. Debt relief comes from Silicon Valley Bank. The first product of the fertility startup is aimed at identifying the healthiest sperm to improve IVF results.
“Oma Fertility is taking the opportunity to bring cutting-edge technological advances to the fertility space, meeting the demands of a growing infertility rate,” co-founder and CEO Gurget Singh said in a statement. “Our mission is to improve outcomes for more families facing fertility problems, and we strive to create a place where anyone who wants to have a child has access to the most modern, successful fertility treatments.”
Payer-focused healthcare company Abacus Insights earned $ 28 million in C-Series funding, leading to an overall increase of $ 81 million.
The round was led by MultiPlan Corporation with the Blue Venture Fund, CRV, .406 Ventures, Horizon Healthcare Services Inc. and Echo Health Ventures. Abacus picked it up $ 35 million in Series B funding in 2020
He plans to use the investment to grow his business, improve his platform and hire more employees.
“This new funding confirms our company’s mission, which is to help health plans release health data,” said CEO and founder Dr. Patel Past said in a statement. “This allows consumers to make better health choices and doctors to make more informed treatment decisions. Payers also use the platform to boost business efficiency, which further reduces costs for their members. We are proud to partner with MultiPlan, given their leading position in data and analysis, serving almost every payer in the country. “
Sesame’s self-paying healthcare market raised $ 27 million in a G-series Serie B round.
Virgin Group, TeleSoft Partners, FMZ Ventures, General Catalyst, Industry Ventures, Coefficient Capital, Giant Ventures and Alumni Ventures Group also participated in the increase. Sesame plans to use the capital to grow the startup and launch its subscription program in beta.
“Sesame provides greater access to health care for a significant percentage of the population, and we are inspired by the company’s mission to drive better outcomes for patients in underserved communities,” said Katie Friedman, GV’s executive partner.
“Sesame is a fascinating opportunity to develop a dynamic market on a scale different from any in the current US health ecosystem. We are excited to partner with David Goldhill and the entire Sesame team as they move into this next phase of growth. ”